Crinecerfont Capsule shortage
To Be Discontinued 1 presentations · 1 manufacturers · first FDA posting Apr 28, 2026 · last update Apr 28, 2026
Manufacturers: Neurocrine Biosciences, Inc.
Stated reasons (per FDA): Not stated
More info: FDA Drug Shortages Database · ASHP drug shortages list (search there for this drug)
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Crenessity, Capsule, 25 mg (NDC 70370-5025-1) | Neurocrine Biosciences, Inc. | To Be Discontinued | — | Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1). | Posted Apr 28, 2026 Updated Apr 28, 2026 Discontinued Apr 28, 2026 |